


2019

medicina

BUENOS AIRES VOL. 79 Supl. IV - 2019

80° Aniversario



MEDICINA

Volumen 79, Supl. IV, págs. 1-338

medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

COMITÉ DE REDACCIÓN

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina

José H. Casabé
Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Isabel A. Lüthy
Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Rodolfo S. Martín
Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina

Guillermo D. Mazzolini
Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina

Rodolfo C. Pucho
Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina

Viviana Ritacco
Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina

Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Argentina

Christiane Dosne Pasqualini
Academia Nacional de Medicina, Argentina

La Tapa (Ver pág. 4)
Atardecer en la tarde
Antonella Ricagni

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 02683675

Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires)

Propietario de la publicación: Fundación Revista Medicina

Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,

1427 Buenos Aires, Argentina

Tel. 5287-3827 Int. 73919 y 4523-6619

e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019

REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

**LXIV Reunión Anual de la
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Reunión Anual de la
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Reunión Anual de la
Sociedad Argentina de Biología (SAB)**

**XXXI Reunión Anual de la
Sociedad Argentina de Protozoología (SAP)**

**IX Reunión Anual de la
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Reunión Científica Regional de la Asociación Argentina
de Ciencia y Tecnología de Animales de Laboratorio
(AACyTAL)**

**con la participación de
The Histochemical Society**

13 - 16 de noviembre de 2019
Hotel 13 de Julio - Mar del Plata

EDITORES RESPONSABLES

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

studies, we demonstrated that autophagy participates in the elimination of intracellular amastigotes by means of xenophagy, a pathway of capture and degradation of intracellular microorganisms dependent on autophagy. Due to a direct cytotoxic action of the UA on epimastigotes, the replicative stage in the insect vector was discarded, we decided to study the action of the UA in the elimination of the amastigotes of *T. cruzi* in the macrophages and the possible participation of the autophagy and other mechanisms in this process. To test this, we infected macrophages with *T. cruzi* Y strain for 24 hours, and then treated the samples for 24, 48 or 72 hours under both control and UA (10 µM) conditions, and evaluated the amount of amastigotes by indirect immunofluorescence and western blot. We also performed cell viability tests with alamar blue to study the UA cytotoxicity on mammalian cells. Xenophagy (by IFI), and ROS generation (by 2',7'-dichlorodihydrofluorescein diacetate reaction) was also tested as two possible mechanisms of action of this drug. Our data show that UA decreases the amount of amastigotes in macrophages. We also observe that UA induces the autophagy pathway, and that LC3, the marker of autophagy, is recruited around amastigotes indicating xenophagy of these parasites. Moreover, the productions of ROS after 24 hours of treatment are increased. We conclude that UA decreases the amount of intracellular amastigotes by multiple mechanisms. UA stimulates the autophagy pathway promoting parasite capture and degradation through xenophagy. On the other hand, UA stimulates the production of ROS, which is toxic for *T. cruzi* but, interestingly, UA not have this effect on non-infected cells. However, we do not rule out a direct action of the UA on amastigotes, which we are studying by transmission electron microscopy.

0581 - IN VITRO ANTIVIRAL ACTIVITY OF NORDIHYDROGUAYRETTIC ACID AND ITS TETRAMETHYLATED DERIVATIVE ON ARBOVIRUS WITH MEDICAL-VETERINARY IMPORTANCE

Florencia MARTINEZ (1) | Juan Javier AGUILAR(2) | Marta CONTIGIANI(2) | Susana NUÑEZ MONTOYA(3) | Brenda KONIGHEIM(1)

INSTITUTO DE VIROLOGIA DR. J. M. VANELLA, FACULTAD DE CIENCIAS MEDICAS-UNC /CONICET (1); INSTITUTO DE VIROLOGIA DR. J.M. VANELLA-FACULTAD DE CIENCIAS MEDICAS-UNC (2); CONICET- INSTITUTO MULTIDISCIPLINARIO DE BIOLOGÍA VEGETAL (IMBIV)/UNC (3)

In the search for new antiviral agents from native plant species, we began studying *Larrea divaricata* CAV. (Zigophyllaceae) and its main metabolite: nordihydroguaiaretic acid (NDGA). The antiviral effect of NDGA and its derivatives has been reported in numerous studies, the range of viruses evaluated is wide. However, there are few reports on arboviruses. We aimed to evaluate the in vitro effect of NDGA and its tetra methylated derivative, NDGA-4-M, on arbovirus: Chikungunya (CHIKV), St. Louis encephalitis (SLEV), Bunyamwera (BUNV) and Dengue types 1 and 4 (DENV-1, DENV-4), trying to establish the stages of the viral replication cycle affected. Cytotoxicity was assessed as a measure of the host cell viability in vitro by the neutral red uptake method. The virucidal and antiviral effects were evaluated by the plaque forming units (PFU) method. To those compounds showing active, we studied their action in several stages of the viral replication cycle, by using the UFP reduction method at different treatment times. Concentration of NDGA and NDGA-4-M causing 50 % of cytotoxicity (CC50) in LLC-MK2 cells were 115.7 µM and 7.8 µM respectively. NDGA-4-M was not able to inhibit any of the viruses tested. Although NDGA was not active also on CHIKV, SLEV and DENV-4, it was active on DENV-1 and BUNV with a selectivity index of 8.4 and 5.2 respectively. NDGA also produced an inhibition greater than 3 logarithms on DENV-1 when assessing virucidal activity. When evaluating the NDGA effect at different times of the viral replication cycle, it was determined that NDGA acts during the first two hours post-

internalization (p.i.) on DENV-1 infection. By contrast, it was active all the time p.i. viral of the BUNV and, to a lesser extent, when cells were pre-treated before infection. Since there is currently no specific antiviral therapy available for the effective clinical treatment of infections produced by arboviruses, these results make NDGA a promising drug to treat these infections.

0606 - ASSESSMENT OF RESISTANCE PATTERNS OF ANTIMICROBIALS WITH HIGH IMPORTANCE IN HUMAN HEALTH, IN DIAGNOSED BOVINE NEUMONIA.

Guadalupe DE YANIZ (1) | Andrea FIORENTINO(2) | Fernando PAOLICCHI(2) | Angel BENCE(1) | Paula DOMINIGUEZ(1) | Laureano SCHOFS(1) | Sergio SANCHEZ BRUNI(1)

CIVETAN (CONICET-CICPBA-UNCPBA), FACULTAD DE CIENCIAS VETERINARIAS, UNCPBA, TANDIL (1); INTA-BALCARCE (2)

Bovine respiratory disease (BRD) is the most important illness in feedlot cattle, where animals are subjected to high pharmacological pressure with antimicrobial (ATM) drugs for prevention or treatment. Some of ATM used for prevention or treatment of BRD, are considered by OMS as very high and high importance for human health. The aim of this study was to assess the resistance frequency of *Pasteurella multocida* and *Mannheimia haemolytica* isolated from dead cattle with BRD, in order to determine the bacterial resistance. This trial involved the analysis of 41 isolated strains from 38 dead animals. Antimicrobial susceptibility testing was performed on all isolates strains using broth microdilution and a commercially available bovine/porcine panel (Sensititre®; Trek Diagnostic Systems, Cleveland, OH, USA). The frequency of resistance for the group I of antimicrobials (agents of very high importance to human health-Fluorquinolones and 3rd generation of Cephalosporines) was a 0% for the 2 bacteria assayed. However, the frequency of resistance for Category II antimicrobials (high importance to human health—aminoglycosides, macrolides and lincosamides) was variable. Thus, the resistance pattern obtained for clindamycin was 47.6 and 55 % for either *P. multocida* and *M. haemolytica*, whilst for tilosyn was 19 and 100 %, respectively. The 21.9 % of the strains analyzed did not show resistance to any class of the antimicrobials tested. Regarding the multiresistance pattern, the 26.9 % of the strains showed resistance to only one antimicrobial group while the 51.2 % of the strains showed resistance to 2-4 antimicrobials. *M. haemolytica* resulted the bacteria with the highest resistance levels in animals died by BRD disease. The determination of the frequency of resistance pattern is essential to rationalize the therapeutic in animals subjected to high pharmacological pressure, in order to design new treatment interventions for reducing the development of bacterial resistance.

0614 - HIGH-THROUGHPUT MUTATIONAL ANALYSIS OF TRYPANOSOMA CRUZI ANTIGENIC EPITOPES REVEAL CONSISTENT CONSERVATION OF KEY RESIDUES ACROSS HUMAN CHAGAS DISEASE POPULATIONS.

Leonel BRACCO (1) | Janine RAMSEY(2) | Melissa NOLAN(3) | Faustino TORRICO(4) | Iván MARCIPAR(5) | Jaime ALTCHER(6) | Norival Jr KESPER(7) | Juan Carlos VILLAR(8) | Fernán AGÜERO(1)

INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS (IIB-UNSAM-CONICET) (1); INSTITUTO NACIONAL DE SALUD PÚBLICA (2); UNIVERSITY OF SOUTH CAROLINA (3); FUNDACIÓN CEADES (4); UNIVERSIDAD NACIONAL DEL LITORAL (5); HOSPITAL DE NIÑOS "RICARDO GUTIERREZ" (6); INSTITUTO DE MEDICINA TROPICAL "DR. FELIX PIFANO" (7); UNIVERSIDAD AUTÓNOMA DE BUCAMARANGA (8)

Chagas Disease is a major health problem for which no vaccine for public health interventions are yet available. Diagnosis is essential